免疫疗法在患有晚期肝细胞癌的患者的延续效应
Chien-Huai Chuang1,2,3, Ching-Tso Chen2,3,4, Chih-Hung Hsu1,2,3
1Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.
Cancer immunology, immunotherapy : CII
|May 16, 2025
概括
在晚期肝细胞癌 (HCC) 中,一线免疫检查点抑制剂 (ICI) 显示出转移效应. 最初ICI治疗的临床益处显著改善了随后治疗中的存活率和无进展存活率.
科学领域:
- 肝胆道癌症 肝胆道癌症
- 免疫治疗是一种免疫疗法.
- 在瘤学瘤学.
背景情况:
- 晚期肝细胞癌 (HCC) 通常用组合免疫疗法治疗.
- 对初始免疫检查点抑制剂 (ICI) 的反应可能会影响随后的治疗疗效 (延续效应).
- 这种效应归因于ICI治疗后的免疫记忆和持续的免疫激活.
研究的目的:
- 研究一线免疫检查点抑制剂 (ICI) 治疗在晚期肝细胞癌 (HCC) 中的延续效应.
- 分析一线ICI治疗效益与救援疗法的结果之间的关联.
主要方法:
- 对接受一线ICI治疗的60名晚期HCC患者的回顾性分析 (2017年12月至2021年12月).
- 患者在一线治疗中取得进展,并接受了二线全身治疗.
- 包括进展后生存 (PPS) 和二线无进展生存 (PFS) 在内的结果与使用多酶抑制剂 (MKIs) 的历史队列进行了比较.
主要成果:
- 第一线ICI治疗在76.7%的患者中显示出临床益处.
- 从一线ICI中获得临床益处的患者具有显著更长的PPS (14.6vs4.9个月) 和二线PFS (3.6vs1.6个月).
- 一线ICI临床益处是改善PPS和二线PFS的独立预测因素,与一线MKI治疗不同.
结论:
- 第一线免疫检查点抑制剂 (ICI) 治疗的临床益处与先进的HCC中改善后进展生存率和二线无进展生存率有关.
- 这些发现表明,在先进的HCC患者中,一线ICI治疗的延续效应.
更多相关视频
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
1.2K
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
5.1K
相关概念视频
01:27Tumor Immunotherapy
493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493
01:40Cell-mediated Immune Responses
67.9K
Overview
67.9K